Correspondence 0001628280-24-015480 from Skye Bioscience, Inc. (SKYE) (CIK 0001516551) (SKYE)
Skye Bioscience, Inc. (SKYE) (CIK 0001516551)
Date: April 9, 2024 · CIK: 0001516551 · Accession: 0001628280-24-015480
AI Filing Summary & Sentiment
File numbers found in text: 333-278286
Letter
VIA EDGAR Division of Corporation Finance Attention: Lauren Hamill Re: Skye Bioscience, Inc. Registration Statement on Form S-1 (File No. 333-278286) Request for Acceleration
Dear Ms. Hamill:
We hereby withdraw our prior request for effectiveness as of April 11, 2024. Pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission promulgated under the Securities Act of 1933, as amended, Skye Bioscience, Inc. hereby simultaneously requests that the effective date of the above-captioned Registration Statement on Form S-1 be accelerated to 4:15 p.m., Eastern Time, on April 10, 2024, or as soon as practicable thereafter.
Please contact John Hensley of Morrison & Foerster LLP via telephone at (512) 617-0661 or via e-mail at JHensley@mofo.com with any questions you may have. In addition, please notify Mr. Hensley when this request for acceleration has been granted.
Sincerely,
Skye Bioscience, Inc.
Show Raw Text
CORRESP 1 filename1.htm Document Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 April 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: Skye Bioscience, Inc. Registration Statement on Form S-1 (File No. 333-278286) Request for Acceleration Dear Ms. Hamill: We hereby withdraw our prior request for effectiveness as of April 11, 2024. Pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission promulgated under the Securities Act of 1933, as amended, Skye Bioscience, Inc. hereby simultaneously requests that the effective date of the above-captioned Registration Statement on Form S-1 be accelerated to 4:15 p.m., Eastern Time, on April 10, 2024, or as soon as practicable thereafter. Please contact John Hensley of Morrison & Foerster LLP via telephone at (512) 617-0661 or via e-mail at JHensley@mofo.com with any questions you may have. In addition, please notify Mr. Hensley when this request for acceleration has been granted. Sincerely, Skye Bioscience, Inc. /s/ Kaitlyn Arsenault Name: Kaitlyn Arsenault Title: Chief Financial Officer cc: Punit Dhillon, Chief Executive Officer John Hensley